Lisa Gill

Patrick Conway and Optum Rx leadership covered infusion, biosimilar uptake and specialty volume growth, but the external-client integration point got only general color.

DeVeydt explicitly declined to label the foundation and platform investments one time, and told investors not to carve out items in either direction.

Wayne explained Optum Insight's back-half weighting reflects decommissioning legacy non-AI products and reinvesting in AI-based replacements, with benefits expected in H2. Optum Rx onboarded 800 new clients with majority of run rate flowing into next year.

Jon Mahrt confirmed impacts accounted for in guidance. GPO already domiciled in U.S., no impact. Expressed concern about Tennessee legislation harming access for 150,000 patients with complex conditions. Highlighted leadership position with 100% cost-based reimbursement for independents and Price Edge serving 14 million members.

Hunter said Part D seasonality more even through year with IRA implementation. Benefit design aligned with industry evolution. Pharmacy cost trend in 2025 on balance gives good belief in 2026 outlook. New clients choosing OptumRx for affordability, transparency and execution. Generates more than $100 billion in savings annually through manufacturer and pharmacy negotiations.

Noel said utilization tracking in line across all product lines including commercial, ACA, Medicare and Medicaid. Part D also tracking in line. Normal seasonality with 60% earnings in first half and 40% in second half. Slight bias toward first half this year given trends. AEP seasonal ramp also a factor.

Hemsley identified OptumInsight, AI agenda, and fintech platform as underinvested areas needing attention. Plans to accelerate AI-first orientation across enterprise. Expects good contributions for 2026 but real acceleration in 2027-2028. Divya described AI-powered RCM solution already launched with more coming. Cost opportunities at corporate level being reallocated to high-margin business investments.

Witty said pleased with 2026 rate recognition of reality, sees end of transition period for absorbing funding pressure. Acknowledged further V28 step-down in 2026 but believes Q1 2025 issues largely fixable in-year to support stronger 2026 performance and ramp back to target growth rate.

Witty reframed PBM debate toward pharmaceutical pricing as root cause. Announced 100% rebate pass-through commitment by 2028 to remove criticism. Currently at 98%. Positioned PBM as only effective mechanism holding pharma accountable.

Brian gave 2026 retention over 97%, 2027 mid-90s or higher, and 2027 new business above the prior two seasons combined, plus specialty carve-out momentum. Direct.

Ann identified three specialty drivers: volume growth, biosimilar/specialty generic mix shift improving margins, and Shields contribution. PBS costs in line with guidance with Signature spending ramping in the back half.

David confirmed similar margin profile and intact growth algorithm under rebate-free model. GPO move from Switzerland to US could impact effective tax rate up to 1% if unmitigated, deemed manageable against 10-14% long-term EPS growth algorithm.

David confirmed Evernorth long-term 5-8% algorithm intact but 2026 will be off-algorithm due to PBS investments and large client renewals. Brian outlined 3 modeling categories: large clients ($90B revenue, new run rate through decade), transition spend (dissipates after 2027), and balance of book (comparable earnings contributions from rebate-free model).

Brian reported mid-90s+ PBM retention for 2026 with Prime Therapeutics multiyear renewal. Active selling season with affordability as #1 employer focus. David praised Arkansas TRO outcome, said legislation would break continuity of care and restrict choice.

Brian outlined multi-formulary approach with principles of competition, choice, and supply chain resilience. EverNorth 50%+ employer coverage, Cigna Healthcare 15-20%, both stable YoY.

David strongly opposed the bill as limiting choice and increasing costs, but noted Arkansas is a relatively small market for Cigna Corporation.

David said vast majority of rebates already passed through, new reforms targeted at patients facing financial dislocation in deductible phases. Eric confirmed enhancements will be default approach.

Eva attributed the outperformance to US MSO strength and specialty utilization; ex-Florida Cancer loss and OneOncology, OI growth was double digits, up from 7% last quarter. Bob reiterated confidence in staying within the long-term range but declined to endorse a specific FY27 number.

Jim walked through Q2 revenue and OI drivers in detail. $2B IRA WAC reductions were 3% US revenue headwind. Core OI growth of 7% ex OneOncology and customer loss. Bob emphasized WAC changes and biosimilar shifts are lower-margin, so OI impact is manageable. Confidence in long-term 7-10% organic OI growth guidance.

Bob emphasized health system specialty growth alongside physician practices. Cencora brings capabilities to help health systems execute their specialty strategies. Jim noted Q2 interest expense will be ~2x Q1 and oncology customer headwind continues through Q3.

Bob framed portfolio reshaping as disciplined strategic focus, not commentary on business quality. MSOs are where capital and management attention will be concentrated. Jim added RCA exceeded expectations and OneOncology driving strong specialty sales growth.

Jim explained revenue moderation from biosimilar conversions (Part D and Part B), decelerating GLP-1 growth (19% vs prior quarters), and loss of a high-revenue low-margin grocery customer. OI outpacing revenue due to specialty mix and biosimilar margin benefits. International seeing better clinical trial start statistics as positive leading indicator.

Jim confirmed no material tariff impacts called out. Manufacturers are importer of record. Focus is on ensuring patient access and supporting upstream/downstream partners through uncertainty.

Jim explained three factors: GLP-1 growth assumed higher in Q1 than balance of year (big revenue impact, minimal OI impact), Humira biosimilar conversion, and RCA adding OI not revenue.

Bob Mauch affirmed strategic continuity, emphasized talent investments and customer-centric approach. Addressed IRA volume question by noting continued strong utilization trends.

Gail detailed one-time 2026 investments (Sydney Health at 22 million members, CareBridge, Health OS) enabling medical-cost and efficiency leverage that supports the at least 12% 2027 growth target.

Mark pushed back on characterization, stating Carelon Rx performance was in line with expectations and consistent with mid-5% full year margin guide. Improvement seen in specialty and home dispensing.

Mark noted regulatory direction toward transparency is consistent with Carelon Rx's existing model, which offers clients flexibility including rebate pass-throughs and transparent fee-based arrangements.

Mark clarified: $3.75 nonrecurring items in FY2025 ($2.75 more favorable than October guidance), entirely from tax outperformance. With that outperformance, pulled forward a quarter of ~$1 incremental investments plus deployed additional $0.25 toward retention and workforce investments.

Mark confirmed material marketplace contraction expected under expiration with meaningfully lower enrollment and higher morbidity risk pool per CBO estimates. Gail emphasized readiness for range of outcomes and willingness to work with states on continued access.

Gail confirmed MA trends elevated but in line. Felicia described 2026 bid strategy focused on margin normalization through HMO and duals prioritization.

Mark provided detailed Part D IRA context: lower $2,000 OOP cap accelerates catastrophic coverage, offset by enhanced CMS direct subsidies. Reversed usual quarterly seasonality pattern.

Mark broke out MLR increase into three drivers: Medicare business mix including Part D changes, CareBridge acquisition running at ~20bps higher MLR, and prudent cost trend assumptions.

Adam gave the organic/acquisition split and specialty-vs-routine dynamics; Julia separately quantified the ACA assumption at 30 basis points.

Adam quantified weather at $15M, organic volume would have been ~2% without it. Julia confirmed ACA impact immaterial in Q1 but too early for firm conclusions. Enrollment slightly better than expected. 30 bps estimate maintained in full-year guidance.

Julia confirmed 30 bps ACA volume headwind in 2026 guidance, noted enrollment better than anticipated. Weather impact in January reflected in guidance. Earnings cadence expected roughly 50/50 first/second half. Margin expansion continues but not guided specifically.

Adam broke down the 40 bps: $13M from FX, rest from acquisition timing (some closed later, a few fell into next year). Pipeline remains strong. Dismissed ACA anticipation as utilization driver given physician capacity constraints.

Adam confirmed 20-25% of contracts renew annually on 3-5 year terms. Unit price flat, renewals secured at reasonable terms. Hospital deals help in payer discussions by demonstrating cost reductions for the system.

Adam said animal testing is 10-15% of BLS revenue, very small for enterprise. 90 PhDs/MDs working on non-animal models. No significant impact expected this year.

Adam clarified the 3x growth applies to oncology, women's health, neurology, and autoimmune specifically, not all esoteric. Believes LH is gaining market share.

Adam confirmed minimal financial impact since LH already submits to New York State. Some incremental systems costs but within guidance ranges.

Brian called 340B reform premature to quantify given the ongoing comment period and noted IRA Part D does not take effect until January 2028; the response was largely qualitative.

Britt confirmed organic oncology growth ~13%, weather had no quarterly impact as January demand recovered within the quarter, and PRISM/Core acquisitions are integrating well.

Britt attributed O&M margin improvement to positive mix from Florida Cancer and Prism Vision provider additions, continued oncology specialty product growth, and early AI automation benefits expected to build over time.

Britt attributed RxTS margin expansion to favorable mix from technology services growth including new programs, access solutions, and GLP-1 prior authorizations. Flagged higher investment spending in second half of year.

Britt confirmed Rite Aid impact is immaterial to FY2026 operations. Highlighted strong momentum from stable utilization, specialty growth, new customer cycling, and 6-7% acquisition contribution.

Brian detailed diversified sourcing across NorthStar generic program with no fixed capital in any country. Britt confirmed tariffs incorporated in guidance with no material impact expected.

Britt clarified the impact is limited to one product with one customer and is purely a revenue issue, declining to speculate on future biosimilar transitions.

Britt directly attributed growth to consistent utilization, a new strategic partner, specialty, and oncology.